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Summary Introduction
In most patients with isolated unilateral retinoblastoma,
Inactivation of both alleles of the retinoblastoma-sus-tumor development is initiated by somatic inactivation of
ceptibility gene (RB1) is the crucial event in the develop-both alleles of the RB1 gene. However, some of these
ment of retinoblastoma, a malignant tumor that origi-patients can transmit retinoblastoma predisposition to
nates from embryonal retinal cells (Knudson 1971;their offspring. To determine the frequency and nature of
Cavenee et al. 1983; Friend et al. 1986). Mutations inconstitutional RB1-gene mutations in patients with iso-
one allele of this gene lead to a predisposition for retino-lated unilateral retinoblastoma, we analyzed DNA from
blastoma, which is transmitted as an autosomal domi-peripheral blood and from tumor tissue. The analysis of
nant trait if the mutation is present in germ-line cells.tumors from 54 (71%) of 76 informative patients showed
Tumor development is initiated by inactivation of theloss of constitutional heterozygosity (LOH) at intragenic
second RB1 allele. Since mutations in the second alleleloci. Three of 13 uninformative patients had constitutional
can occur independently in several cells, multiple tumordeletions. For 39 randomly selected tumors, SSCP, hetero-
foci arise in most individuals who have inherited a pre-duplex analysis, sequencing, and Southern blot analysis
disposing RB1 mutation. In early childhood, the riskwere used to identify mutations. Mutations were detected
for the development of new tumors decreases, since thein 21 (91%) of 23 tumors with LOH. In 6 (38%) of 16
population of cells with a potential for tumor formationtumors without LOH, one mutation was detected, and in
declines rapidly (Knudson 1971).9 (56%) of the tumors without LOH, bothmutations were
All patients with familial, bilateral, or unilateralfound. Thus, a total of 45 mutations were identiﬁed in
multifocal retinoblastoma are regarded as carriers of antumors of 36 patients. Thirty-nine of the mutations—in-
RB1 germ-line mutation (Vogel 1979). In addition, sur-cluding 34 small mutations, 2 large structural alterations,
vivors of isolated unilateral retinoblastoma may haveand hypermethylation in 3 tumors—were not detected in
affected children. Estimates of the proportion of heredi-the corresponding peripheral blood DNA. In 6 (17%) of
tary retinoblastoma in patients with isolated unilateralthe 36 patients, a mutation was detected in constitutional
tumors, on the basis of surveys of the occurrence ofDNA, and 1 of these mutations is known to be associated
retinoblastoma in offspring, have resulted in differentwith reduced expressivity. The presence of a constitutional
ﬁgures. Most widely cited are those reported by Vogelmutation was not associated with an early age at treat-
(1979). Assuming a penetrance of 90% in children withment. In 1 patient, somatic mosaicism was demonstrated
a germ-line mutation inherited from a unilaterally af-by molecular analysis of DNA and RNA from peripheral
fected parent, he estimated that 10%–12% of isolatedblood. In 2 patients without a detectable mutation in pe-
ripheral blood, mosaicism was suggested because 1 of the unilateral cases are caused by germ-cell mutations. In a
patients showed multifocal tumors and the other later de- recent report, Draper et al. (1992) used the method of
veloped bilateral retinoblastoma. In conclusion, our results maximum likelihood to analyze data from a large popu-
emphasize that the manifestation and transmissibility of lation-based group of patients. By following up on se-
retinoblastoma depend on the nature of the ﬁrst mutation, lected groups of patients, they estimated a 1.7% proba-
its time in development, and the number and types of cells bility that a patient with unilateral retinoblastoma and
that are affected. no family history of retinoblastoma in fact carries a
germ-line mutation, when a penetrance of 90% is as-
sumed. However, it has been noted that, in children,
the penetrance and the expressivity of an RB1 mutationReceived March 3, 1997; accepted for publication May 28, 1997.
Address for correspondence and reprints: Dr. Dietmar R. Lohmann, apparently are increased with increased expressivity in
Institut fu¨r Humangenetik, Hufelandstrasse 55, D-45122 Essen, Ger- the parents (Briard-Guillemot et al. 1974; Matsunaga
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2.3% probability that a patient with isolated unilateral suggested in 2 of the patients without a detectable muta-
tion in peripheral blood, because 1 patient showed tworetinoblastoma carries a germ-line mutation.
Early diagnosis of retinoblastoma is important for the spatially distinct tumor foci in one eye and the other
later developed a new tumor in the fellow eye. Thus,prognosis of both vision and survival. Consequently,
repeated ophthalmological examinations are necessary owing to the presence of mosaicism in some patients,
analysis of DNA from tumor cells and from constitu-for infant relatives of patients with retinoblastoma (Mu-
sarella and Gallie 1987). In hereditary retinoblastoma, tional cells is not sufﬁcient to conﬁrm or to exclude
unambiguously hereditary retinoblastoma in patientsknowledge of the individual germ-line mutation allows
for accurate risk prediction for relatives (Dunn et al. with isolated unilateral disease. If somatic mosaicism is
not rare in patients with isolated retinoblastoma, current1989; Yandell et al. 1989). Mutation screening of pe-
ripheral blood DNA can detect oncogenic mutations, concepts of genetic counseling and risk prediction have
to be revised accordingly.for most patients with bilateral isolated retinoblastoma
or with familial retinoblastoma (Lohmann et al. 1996).
A comparison of the costs of molecular versus conven- Patients, Material, and Methods
tional screening approaches has indicated that muta-
Patients and Tumorstional analysis will help to reduce health-care expenses
(Noorani et al. 1996), and, therefore, DNA testing offers Vital samples of retinoblastoma and of peripheral
economic advantages, in addition to individual beneﬁts blood were obtained from 89 patients with isolated uni-
to families. lateral tumors. The diagnosis was established by use of
With the exception of cytogenetic deletions involving current histopathologic criteria. In almost all the pa-
13q14, few constitutional mutations have been reported tients, enucleation had to be performed because the tu-
in patients with isolated unilateral retinoblastoma. By mors involved more than one-half of the retina. In a few
screening peripheral blood DNA, Blanquet et al. (1995) patients, enucleation was performed because a smaller
identiﬁed bona ﬁde oncogenic mutations in 4 (7.1%) of tumor was located in the fovea. Two of these patients
56 patients with unifocal isolated retinoblastoma. How- showed distinct multifocal tumor growth, and, for both
ever, in the same study, mutations were identiﬁed in patients, the largest tumor was examined. Tumor and
only 46 (26%) of 176 patients with hereditary retino- blood samples were stored at070C and020C, respec-
blastoma. This low rate of detection indicates that muta- tively, until DNA was extracted by use of standard pro-
tions also may have been missed in patients with the tocols (Kunkel et al. 1977). DNA was extracted from
unifocal disease. In general, since current methods do formalin-ﬁxed, parafﬁn-embedded samples, as described
not detect all mutations, results obtained by screening elsewhere (Wright and Manos 1990).
of constitutional DNA should not be used to estimate
PCR-Mediated Genotyping of DNA Polymorphismsthe proportion of carriers of mutations, among patients
with isolated unilateral retinoblastoma, and such results To determine loss of constitutional heterozygosity
are of limited value for accurate risk prediction for rela- (LOH) in tumors, short-tandem-repeat (STR) loci RBi2,
tives. It has been inferred from the two-step inactivation located in intron 2 of the RB1 gene (Toguchida et al.
mechanism that, if one of the two oncogenic RB1 muta- 1993), and RB1.20, located in intron 20 of the RB1
tions identiﬁed in the tumor also is present in constitu- gene (Yandell and Dryja 1989), were ampliﬁed by PCR,
tional cells, a patient has hereditary retinoblastoma, as described in a previous study (Brandt et al. 1992),
whereas the absence of both oncogenic mutations proves and were analyzed on an ABI 373 sequencer, by use of
that the patient has the nonhereditary disease (Dunn et the Genescan software (Applied Biosystems). In patients
al. 1989; Yandell et al. 1989). Consequently, mutational without LOH in the tumor, loci D13S262 (Genome Da-
analysis is required in both tumor and constitutional tabase [GDB] G00-199-226) and D13S284 (GDB G00-
cells. However, since only a few patients have been stud- 200-238), both of which are linked closely to the RB1
ied previously by use of this approach (Yandell et al. gene, also were investigated. In patients with LOH, the
1989; Hogg et al. 1992; Shimizu et al. 1994), no reliable STR polymorphisms D13S115 (mapped to 13q11-
data exist for the frequency and the nature of constitu- q12.1; GDB G00-182-248) and D13S193 (mapped to
tional mutations in patients with isolated unilateral reti- 13q31-q32; GDB G00-189-227) were analyzed, in addi-
noblastoma. tion to the intragenic loci. When available, parents were
Here we report the results of a mutational analysis of genotyped, to trace the parental origin of the allele lost
tumors from 39 patients with isolated unilateral retino- in tumor cells.
blastomas. RB1 mutations were identiﬁed in 36 tumors.
PCR Ampliﬁcation, Screening for Small Mutations, andIn 6 patients with no signs of multifocal disease, an RB1
Sequencingmutation also was detected in peripheral blood DNA.
In 1 patient, somatic mosaicism was demonstrated by PCR was performed by use of the primers and condi-
tions described in previous studies (Lohmann et al.use of molecular analysis. Somatic mosaicism also was
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1994a; Lohmann et al. 1996). An additional primer fragments of distinguishable size that cover different
parts of the RB1 gene (B. Brandt, B. Horsthemke, and(RB1lm [5-CCCTCGCCCAAGAACCCAGAATC-3])
was used to improve the ampliﬁcation efﬁciency of the D. R. Lohmann, unpublished data).
promoter and the exon 1 region. Nonisotopic SSCP was
Statistical Analysisperformed as described in a previous study (Lohmann
To test ﬁndings reported by Kato et al. (1993; 1994),et al. 1996). In addition, tumors without LOH at both
the distribution of the age at the time of operation wasintragenic and linked loci were analyzed by hetero-
analyzed by use of the same procedures. The proportionduplex analysis (Ganguly et al. 1993; Lohmann et al.
of patients who had not yet had an operation was plot-1996). Exons 1, 5, and 14 and the promoter also were
ted as a function of time, by application of the Kaplan-screened for mutations, by use of sequencing. PCR prod-
Meier method, and the curves were compared by use ofucts were puriﬁed in microcon 100 ﬁltration units (Ami-
the log-rank test (JMP software, version 3.1.6, for thecon) and were used as templates for cycle-sequencing
Macintosh; SAS Institute). The same method was usedreactions (ABI Prism Ready Reaction Kit with polymer-
to compare patients with and those without RB1 muta-ase FS; Applied Biosystems). Sequence analysis was per-
tions in peripheral blood.formed on a 310 Genetic Analyzer (Applied Biosystems).
Sequence analysis or, if applicable, restriction-enzyme
digestion of PCR products was used to identify mutation Results
carriers, among parents and siblings of patients with a
Testing for LOH in Tumorsconstitutional mutation.
Constitutional heterozygosity of polymorphic loci
Reverse-Transcription (RT) PCR and the Cloning and within the RB1 gene was observed in 76 (85%) of 89
Typing of PCR Products patients (ﬁg. 1). In tumors from 22 (29%) of the 76
informative patients, heterozygosity was retained. Fur-To examine the consequences of a potential splice-
ther investigation at D13S262 or at D13S284, in 19 ofsite mutation identiﬁed in one patient, whole-blood
these patients, also showed no allele loss in 16 of 17RNA was isolated by use of the method of Chomczyn-
patients that were informative at these closely linkedski and Sacchi (1987) and was reverse-transcribed
loci. The tumor enucleated from a 7-mo-old patientprimed by random oligos (GeneAmp RNA PCR Kit;
showed allele loss at D13S262, whereas heterozygosityPerkin Elmer). For PCR ampliﬁcation and sequenc-
was retained at the intragenic locus RBi2. In this tumor,ing, primers RBc9se (5-GGACTTGTAACATCT-
a homozygous deletion was identiﬁed by the SouthernAATGG-3), RBc11se (5-CCTTGATGAAGAGGT-
blot genotyping of two intragenic RFLPs. This indicatedGAATG-3), RBc13se (5-CTGCACAGTGAATCC-
that ampliﬁcation of nontumorous DNA, which almostAAAAG-3), and RBc16as (5-GCCATTACAACC-
inevitably contaminates samples of primary tumors, hadTCAAGAGC-3) were used. For sequence analysis of
resulted in misleading PCR-based genotype data, for theindividual products, DNA was size fractionated and
locus encompassed by the deletion (Szabo and Kingexcised from agarose gels, eluted through 0.47-mm ﬁl-
1995). This also showed that both oncogenic mutationster units (Millipore), and ampliﬁed by PCR. To conﬁrm
detected in this tumor are of somatic origin. In all otherthe somatic mosaicism suggested by analysis of RNA,
exon 13 was ampliﬁed from peripheral blood DNA,
with primers RBi13se and RBi13as (Lohmann et al.
1994a). The products were cloned and transfected, by
use of a pGEM-T kit (Promega), by following of the
recommended protocols. Individual colonies were
picked directly as templates for PCR with exon 13
primers, and SSCP was used to identify wild-type from
mutant inserts.
Southern Blot Analysis
The methylation status of the CpG island at the 5 end
of the RB1 gene was tested by use of the methylation-
sensitive enzymes BssHII and SacII, as described in a
previous study (Greger et al. 1994). Genotyping of RFLP
Figure 1 Flow chart showing the results of genotyping of intra-loci within the RB1 gene was performed as described in
genic polymorphisms and examination for deletions in peripherala previous study (Greger et al. 1988). To identify struc-
blood DNA and tumor DNA, from 89 patients with isolated unilateral
tural alterations of the RB1 gene, in tumors, Southern retinoblastoma. The groups of patients from which tumors were se-
blots of DNA samples digested with EcoRV were hy- lected randomly for comprehensive mutation analysis are indicated
by an asterisk (*).bridized with a battery of probes that hybridize to ﬁve
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tumors without allele loss, no homozygous deletion was that changes codon 787 from CGA (arginine) to TGA
(stop). In accordance with allele loss at intragenic, cen-detected by Southern blot analysis.
Tumors from 54 (71%) of the 76 informative patients tromeric, and telomeric loci in this tumor, no wild-type
sequence was present at the site of the base substitution.showed LOH within the RB1 gene. The parental origin
of alleles lost was maternal in 14 tumors and paternal We also identiﬁed this mutation in peripheral blood
DNA from the patient (ﬁg. 2). The alleles that were lostin 9 tumors. A subset of tumors with LOH also was
investigated at D13S115 (13q11-q12.1) and at D13S193 in the tumor are of maternal origin, and, therefore, the
mutation is in phase with the paternal haplotype. The(13q31-q32). The centromeric locus showed LOH in
tumors of only 9 (39%) of 23 informative patients, same paternal haplotype is present in the patient’s
brother. Exon 23 PCR products from the analysis of thewhereas at the telomeric locus LOH was detected in
tumors of 15 (79%) of 19 informative patients. In all 4 peripheral blood DNA of the father and of the brother
show a homozygous wild-type TaqI restriction pattern.tumors without telomeric allele loss, heterozygosity also
was retained at the centromeric locus. These ﬁndings argue for a new germinal origin or an
early embryonal origin of the mutation identiﬁed in the
Identiﬁcation of Constitutional Deletions patient. However, the possibility of germinal mosaicism
in the father is not excluded.Patients without constitutional heterozygosity at
intragenic loci were examined for deletions involving In one patient only, a constitutional mutation was
inherited from an unaffected carrier parent. A heterozy-the RB1 gene. Constitutional deletions were identiﬁed
in 3 of 13 uninformative patients. In 2 patients, enu- gous ArT transition (c411ArT; E137D), identiﬁed in
tumor sample M2408, also was found in the constitu-cleated at age 22 mo and age 11 mo, cytogenetic anal-
ysis of peripheral blood lymphocytes showed dele- tional DNA of the patient and of her mother and her
sister. The same type of missense mutation previouslytions of 13q (karyotpes 46,XY,del13[q13-q14.3] and
46,XX,del13[q14-q22], respectively). No chromosomal had been reported to be present in the constitutional
DNA of a patient with bilateral retinoblastoma (Blan-aberration was detected in the parents, and, in 1 of the
2 patients, segregation analysis showed that the deletion quet et al. 1993). Segregation analysis indicated that
the mutation is in phase with the haplotype that washad occurred on the paternal chromosome. None of the
deletions extended into 13q32, and, in line with previous inherited from the grandfather. However, since the
grandfather did not consent to DNA testing, we cannotreports (Brown et al. 1993, 1995), no malformation
was present in either patient. Another patient, who was determine whether this mutation occurred de novo.
In tumor sample M2920, a GrA transition was de-treated at the age of 27 mo, showed an apparently nor-
mal karyotype, but the absence of paternal alleles at tected at the last nucleotide of exon 13 (c1332GrA)
(ﬁg. 3A). In correspondence with LOH at both the intra-RBi2 and RB1.20 was identiﬁed by segregation analysis.
Since the alleles at both D13S262 and D13S284 were genic and the telomeric loci in this tumor, sequence anal-
ysis showed no wild-type G at the site of mutation. Ininherited from both parents, he must have a de novo
deletion involving the paternal RB1 gene. peripheral blood DNA, both the mutant and the wild-
type nucleotides were found at the site of the mutation.
Detection of Small Mutations in Tumors and in This mutation reduces the similarity of the intron 13
Constitutional DNA splice-donor sequence to the consensus sequence of eu-
karyotic splice sites, and, most probably, exon 13 isTumors from 39 patients were randomly selected for
a comprehensive mutational analysis of the RB1 gene. skipped in the mutant transcript (Shapiro and Senapathy
1987; Talerico and Berget 1990). Since a deletion ofAll tumors were screened for mutations, by SSCP. In
addition, in tumors without LOH (n Å 16), hetero- this exon does not alter the reading frame, the mutant
transcript is not suppressed in constitutional cells (Dunnduplex analysis was performed. All exons in all tumors
were investigated; that is, examination of a sample was et al. 1989; Kato et al. 1994), and, therefore, it is possi-
ble to verify the functional consequence of this mutation,not suspended once two oncogenic mutations were
found (Cowell et al. 1994). A total of 40 small mutations by RT-PCR analysis of RNA from peripheral blood.
Gel electrophoresis of RT-PCR products showed a DNAwere identiﬁed in the retinoblastomas of 32 patients
(table 1). For 6 patients (samples M2205, M2408, band of normal length and an additional, evidently less
intense, smaller band (ﬁg. 3B). The individual bandsM2920, G1142, M6301, and M6680), direct sequenc-
ing of PCR products from peripheral blood DNA dem- were excised and sequenced. The larger fragment
showed a regular transcript sequence, whereas exon 13onstrated the presence of 1 of the mutations previously
identiﬁed in the corresponding tumor. For example, was skipped in the smaller product (ﬁg. 3C and D). It
is important to note that the last nucleotide of exon 13,exon 23 PCR products from the analysis of tumor sam-
ple M2205 showed an aberrant SSCP pattern, and se- in the fragment that was spliced regularly, only showed
the wild-type G (ﬁg. 3C). Therefore, the difference inquencing revealed a heterozygous CrT transition, at
position 2359 of the open reading frame (c2359CrT), quantity between normal and mutant RT-PCR products
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Table 1




SAMPLE MUTATION TYPE(S)a SITE SEQUENCEb CONSEQUENCEc DNA Operation Study
Transition Intron 12 IVS12-2ArG Splice acceptor No
G902 67.1 152.5
Loss of paternal allele . . . . . . . . . . . .
G909 Loss of maternal allele . . . . . . . . . . . . 29.0d 114.6
G1142 Transition (CpG) Exon 20 c1982CrT R661W Yes 10.9 90.9
2-bp deletion Exon 3 c369delAT PT at codon 129 No
G1166 17.2 95.6
Loss of maternal allele . . . . . . . . . . . .
Transition (CpG) Exon 14 c1333CrT R445X No
M461 6.0 65.3
LOH . . . . . . . . . . . .
Hypermethylation Promoter . . . Silencing No
M734 29.0 86.7
LOH . . . . . . . . . . . .
Transition (CpG) Exon 17 c1654CrT R552X No
M1324 14.3 68.0
Transition (CpG) Exon 17 c1666CrT R556X No
Transition (CpG) Intron 12 IVS12/1GrA Splice donor No
M1353 3.0 56.5
Loss of maternal allele . . . . . . . . . . . .
100-bp insertion Exon 20 c2065ins100 PT at codon 700 No
M1821 17.0 67.8
Loss of paternal allele . . . . . . . . . . . .
Transition (CpG) Intron 12 IVS12/1GrA Splice donor No
M1886 26.3 76.9
Transition Exon 21 c2158CrT K720X No
Transversion Exon 4 c409GrT E137X No
M1990 25.8 75.4
LOH . . . . . . . . . . . .
Hypermethylation Promoter . . . Silencing No
M2087 15.4 64.5
LOH . . . . . . . . . . . .
Transition (CpG) Exon 23 c2359CrT R787X Yes
M2205 18.3 . . .e
Loss of maternal allele . . . . . . . . . . . .
M2408 Transversion Exon 4 c411ArT E137D Yes 60.0 107.3
Transition Exon 13 c1332GrA Splice donor Yesf
M2920 49.9 94.1
Loss of paternal allele . . . . . . . . . . . .
Transition (CpG) Exon 10 c958CrT R320X No
M3293 10.1 52.6
Transition (CpG) Exon 18 c1735CrT R579X No
Transition Exon 2 c184CrT Q62X No
M3297 16.9 59.3
Transition (CpG) Exon 17 c1654CrT R552X No
Transition Intron 19 IVS19/1GrA Splice donor No
M3619 20.8d 60.5
Loss of paternal allele . . . . . . . . . . . .
Transversion Exon 4 c409GrT E137X No
M3865 22.1 60.2
LOH . . . . . . . . . . . .
10-bp deletion Exon 18 c1735del10 PT at codon 607 No
M4008 10.3 47.5
Hypermethylation Promoter . . . Silencing No
Transition (CpG) Exon 14 c1363CrT R455X No
M4042 7.9 44.8
2-bp deletion Exon 16 c1447delCA PT at codon 491 No
Transition (CpG) Exon 10 c958CrT R320X No
M4372 15.9 50.8
1-bp deletion Exon 20 c2084delT PT at codon 704 No
M4561 No mutation detected . . . . . . . . . . . . 18.0 46.9
M4955 5-bp deletion Exon 3 c336del5 PT at codon 128 No 27.3 58.7
Transition (CpG) Exon 10 c958CrT R320X No
M4957 10.5 41.4
Loss of maternal allele . . . . . . . . . . . .
M4972 Hemizygous deletion . . . . . . . . . No 11.0 41.4
M4976 LOH . . . . . . . . . . . . 24.0 54.5
Transition (CpG) Exon 17 c1666CrT R556X No
M5266 27.7 56.4
LOH . . . . . . . . . . . .
Transition (CpG) Exon 8 c751CrT R251X No
M5450 59.8 87.2
Loss of maternal allele . . . . . . . . . . . .
Transition (CpG) Exon 10 c958CrT R320X No
M5500 15.4 42.7
LOH . . . . . . . . . . . .
1-bp insertion Exon 17 c1585insT PT at codon 554 No
M5682 56.4 82.8
4-bp deletion Exon 18 c1723del4 PT at codon 609 No
(continued )
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SAMPLE MUTATION TYPE(S)a SITE SEQUENCEb CONSEQUENCEc DNA Operation Study
Transversion Intron 3 IVS3/1GrT Splice donor No
M5702 12.5 38.9
Loss of maternal allele . . . . . . . . . . . .
1-bp insertion Exon 19 c1816insT PT at codon 652 No
M5714 32.9 59.4
Loss of maternal allele . . . . . . . . . . . .
1-bp deletion Exon 2 c227delT PT at codon 76 No
M5812 12.7 38.0
Loss of maternal allele . . . . . . . . . . . .
M6301 Transition (CpG) Exon 10 c958CrT R320X Yes 36.2 59.6
Transition (CpG) Exon 11 c1072CrT R358X No
M6306 2.3g 25.6
Loss of paternal allele . . . . . . . . . . . .
M6336 Hemizygous deletion . . . . . . . . . No 23.0 45.5
Transversion Exon 16 c1494TrA Y498X No
M6418 22.7 44.9
Loss of maternal allele . . . . . . . . . . . .
Transition Intron 12 IVS12-1GrA Splice acceptor Yes
M6680 2.4 25.6
8-bp insertion Exon 22 c2244ins8 PT at codon 756 No
a A second mutation was not detected in samples G909, G1142, M2408, M4955, M4972, M4976, M6301, and M6336.
b Notation according to the Ad Hoc Committee on Mutation Nomenclature (1996).
c PT Å premature termination.
d Patient had multifocal unilateral retinoblastoma.
e Patient died at the age of 28.7 mo.
f Allelic imbalance identiﬁed in blood DNA indicates that the mutation is present in a mosaic state.
g Patient developed a new tumor in the other eye at the age of 10 mo.
was not caused by residual correct splicing of mutant and from palpebral conjuctiva. Both samples were het-
erozygous at loci with allele loss in the tumor, and re-transcripts. To examine if this difference was caused
by an imbalance of wild-type and mutant alleles in the striction-enzyme digestion of exon 11 PCR products did
not give any evidence of the presence of the nonsensepatient, the exon 13 sequence was PCR ampliﬁed from
peripheral blood DNA and was cloned into pGEM-T. mutation (ﬁg. 4).
Of 60 individual inserts typed by SSCP, only 11 (18%)
Hypermethylation of the RB1 Promotershowed the mutant pattern, thus suggesting that this
patient is a somatic mosaic for this mutation. The methylation status at the 5 end of the RB1 gene
was determined in all tumors selected for comprehensiveMosaicism also was suggested to be present in two
patients without a detectable mutation in peripheral mutational analysis. Tumors from three patients (sam-
ples M734, M2087, and M4008) showed BssHII/SacIblood. One patient showed two distinct tumor foci, and
the two mutations identiﬁed in the larger tumor (sample and SacII/SacI restriction patterns indicative of hyper-
methylation (table 1). Sequence analysis showed no mu-M3619) were not detected in peripheral blood DNA. In
tumor sample M6306, which was obtained from a pa- tation in the promoter and the exon 1 region of these
tumors. No hypermethylation of the RB1 promoter re-tient without an indication of multifocal disease, a CrT
transition (c1072CrT; R358X) was identiﬁed, and, in gion was detected in peripheral blood DNA from these
patients.accordance with the ﬁnding of allele loss at intragenic,
linked, and centromeric loci in this tumor, no wild-type
Detection of Large Deletionssequence was present at the site of mutation. This muta-
tion was not detected by sequence analysis of peripheral Southern blot hybridization was performed to com-
plete the mutation detection in the tumors selected forblood DNA from this patient. While this study was in
progress, the patient developed a new retinoblastoma, comprehensive analysis. A hybridization probe from
within intron 17 identiﬁed an abnormal EcoRV junctionthus indicating that cells with a predisposing mutation
are present in the retina of the fellow eye. In order to fragment in DNA from tumor sample M4972. In an-
other tumor (sample M6336), densitometric evaluationobtain molecular evidence of mosaicism in this patient,
other tissues were investigated for both of the mutations showed a hemizygous deletion that affected the same
region within the RB1 gene. Both alterations were notidentiﬁed in the enucleated tumor. DNA was obtained
from cells exfoliated from buccal mucous membranes detected in constitutional DNA.
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matic mutations of this kind, all samples were investi-
gated at several polymorphic loci on chromosome 13.
We found LOH in tumors from 54 (71%) of 76 informa-
tive patients, which is consistent with previous reports
(Zhu et al. 1992; Kato et al. 1993). In 14 (61%) of 23
patients with intragenic allele loss, heterozygosity was
retained at a centromeric locus. Although PCR-mediated
genotyping does not allow one to distinguish between
homozygosity and hemizygosity, these data conﬁrm that
nondisjunction is not the foremost mechanism responsi-
ble for LOH in retinoblastoma (Zhu et al. 1992).
Recently, Kato et al. (1995) reported that tumors with
loss of the maternally derived RB1 allele are operated
on later than tumors with loss of the paternal allele. OnFigure 2 Top, Pedigree of family Sch (including the patient from
further investigation of this ﬁnding, they identiﬁed awhich sample M2205 was taken), with the genotypes at intragenic
gene, located near the RB1 gene, that shows exclusivepolymorphic loci. Bottom, Results of restriction-enzyme digestion of
exon 23 PCR products. The older brother (II-1) has inherited the maternal expression (Kato et al. 1996). They hypothe-
same paternal haplotype that is retained in the retinoblastoma sample sized that this gene or other, unidentiﬁed imprinted
(‘‘RB’’) obtained from the patient (II-2) with unilateral retinoblastoma. genes in the same region may be associated with delayed
Almost no 98-bp and 171-bp fragments, which result from TaqI diges-
occurrence of retinoblastoma with maternal allele losstion of wild-type exon 23 PCR products, were detectable in the tumor.
(Kato et al. 1996). However, this hypothesis is chal-Both the father (I-1) and the patient’s brother (II-1) show a wild-type
restriction pattern. The DNA size marker (‘‘M’’) shows fragments of lenged by our data, because we did not observe any
501 bp/489 bp, 404 bp, 331 bp, 242 bp, 190 bp, 147 bp, 111 bp/ difference in the age at operation between patients with
110 bp, and 67 bp (MspI digestion of pUC19 DNA; Fermentas). tumors with maternal allele loss versus those with tu-
mors with paternal allele loss.
Heterozygosity was retained at intragenic loci, in the
Statistical Analysis tumors of 22 informative patients. Szabo and King
(1995) noted that PCRmay not detect homozygous dele-Recently, Kato et al. (1993) reported that, in heredi-
tions in primary tumors, because DNA from nontumor-tary cases, the age at operation for 11 patients with
ous cells inevitably is included in these samples. Theytumors without LOH was lower than that for 12 pa-
predicted that, in tumors with homozygous deletions,tients with tumors showing LOH. We observed a similar
heterozygosity appears to be retained at intragenic locitrend in our set of isolated unilateral patients, but, in
but may be lost at markers outside the deleted region.spite of the large number of tumors investigated, the
Genotyping of ﬂanking loci showed this paradoxicaldifference was too small to reach statistical signiﬁcance
LOH pattern in one of the tumors investigated in this(ﬁg. 5A). In another study of retinoblastomas from 13
study, and a homozygous deletion of somatic origin waspatients with isolated unilateral disease, Kato et al.
identiﬁed by Southern RFLP analysis, as expected.(1995) found that tumors with the loss of a maternal
Thirteen of 89 patients were uninformative at intra-allele were operated on signiﬁcantly later than those
genic polymorphisms. Further analysis showed constitu-showing the loss of a paternal allele. We obtained data
tional cytogenetic deletions in 2 patients and a submicro-on the parental origin of alleles lost, for 23 patients
scopic deletion in another. Studies of the rate ofwith tumors, but we found no association between the
chromosome aberrations have revealed that cytogeneticparental origin of RB1 alleles and the age at operation
deletions involving 13q14 occur in 1%–4% of patients(ﬁg. 5B). We also compared the age at operation for
with isolated unilateral retinoblastoma (Ejima et al.patients with a constitutional mutation with that for
1988; Bunin et al. 1989) and, thus, are in accordancepatients in which neither of the two mutations identiﬁed
with the proportion of 2 (2%) of 89, observed in thisin the tumor was detectable in peripheral blood DNA,
study. However, our ﬁgure underestimates the frequencybut we found no signiﬁcant difference (ﬁg. 5C).
of visible chromosomal changes, because our study does
not include samples of tumors from patients in whomDiscussion
a deletion involving 13q14 was known prior to the diag-
nosis of retinoblastoma.To deﬁne the frequency and nature of constitutional
mutations in isolated unilateral retinoblastoma, we ana- An exhaustive mutational analysis was performed in
the retinoblastomas of 39 patients, in order to identifylyzed tumors and corresponding peripheral blood DNA,
sampled from 89 patients. Several classes of mutation mutations that did not result in LOH. Oncogenic muta-
tions were detected in 21 (91%) of 23 tumors with intra-that cause inactivation of RB1 alleles can be detected as
LOH in tumors (Cavenee et al. 1983). To identify so- genic LOH. In 6 (38%) of 16 tumors without LOH, one
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Figure 3 A, Results of sequence analysis of exon 13 PCR products from tumor DNA from sample M2920 (top), from the corresponding
constitutional DNA (middle), and from the unaffected brother of the patient (‘‘control DNA’’) (bottom). Tumor DNA shows only the mutant
A at the end of exon 13, which is indicated by a dashed line. Both mutant A and wild-type G are detectable in peripheral blood DNA. B,
Results of RT-PCR of RNA from peripheral blood of the patient. The primers RBc11se and RBc16as, which span exons 12–15 of the RB1
gene, were used. The results show a product of normal size (407 bp) and a less intense, smaller band. RT-PCR of RNA from human brain
tissue (‘‘control’’) only shows a product of wild-type length. The DNA size marker (‘‘M’’) shows fragments of the lengths listed in ﬁgure 2. C,
Results of sequence analysis of individual excised RT-PCR products. The normal-sized RT-PCR products from the patient (top) and the control
(bottom) show the regular spliced transcript sequence, whereas exon 13 was skipped in the small RT-PCR product from peripheral blood RNA
of the patient (middle). D, Schematic representation showing the mutation identiﬁed in tumor sample M2920 and showing the regular and the
mutant transcript sequences.
mutation was detected, and, in 9 (56%) tumors without of nucleotide changes at invariant splice donor and ac-
ceptor sites (Shapiro and Senapathy 1987; Nakai andLOH, both mutations were found. In only 1 tumor with-
out LOH, no mutation was determined. Thus, a total of Sakamoto 1994). Since 15 (65%) of 23 single-base sub-
stitutions are transitions at CpG sites, this type of muta-45 mutations were identiﬁed in tumors from 36 patients.
Thirty-nine mutations were not detected in the corre- tion is as predominant in constitutional mutations iden-
tiﬁed in hereditary retinoblastoma (Lohmann et al.sponding constitutional DNA and, thus, are of somatic
origin. The spectrum of somatic mutations includes 34 1996). Whereas the frequent occurrence of transitions
at methylated CpG dinucleotides most probably is duesmall mutations, 2 large structural alterations, and, in
3 tumors, hypermethylation of the 5 end of the RB1 to the hypermutability of 5-methylcytosine (Krawczak
et al. 1992), the recurrence of a c409GrT transversiongene. Corrresponding to previous ﬁndings for hereditary
retinoblastoma, most of the 7 small deletions and 4 in- (E137X), in tumors from two patients (samples M1990
and M3865) and in constitutional DNA from a patientsertions identiﬁed here are associated with homocopoly-
mer tracts and direct repeats (Lohmann et al. 1994b). with bilateral retinoblastoma (Lohmann et al. 1996),
might be caused by a two-step dislocation involvingAll small-length alterations and each of the 18 single-
base substitutions in the open reading frame resulted in transient misalignment with an upstream quasi-repeat
sequence containing a monotonic T run (Kunkel andpremature termination codons. In 5 tumors, formation
of a regularly spliced transcript was precluded, because Soni 1988; Ripley 1990; Hogg et al. 1993).
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deletions affecting the middle of the RB1 gene was to
be expected and does not indicate that this region is
prone to somatic deletions (Fung et al. 1987).
To date, aberrant methylation at the 5 CpG island
of the RB1 gene, which is constitutively unmethylated,
has been reported in the tumors of 12 (11%) of 106
patients with isolated unilateral retinoblastoma (Greger
et al. 1989, 1994; Sakai et al. 1991b; this study). Al-
though we performed an exhaustive mutational analysis
of tumors with hypermethylation, no structural alter-
ations were found in 2 tumors with LOH, and the tumor
without allele loss showed only one heterozygous muta-
tion. Thus, our ﬁndings support the hypothesis that hyp-
ermethylation is functionally equivalent to an inactivat-
ing structural mutation. Aberrant methylation is notFigure 4 Top, Pedigree of family Bie (including the patient from
speciﬁc for the RB1 gene but has been found to be associ-which sample M6306 was taken), with the genotypes at polymorphic
ated with transcriptional silencing of several tumor sup-loci. Bottom, Results of restriction-enzyme digestion of exon 11 PCR
products. DNA from peripheral blood (lane PB) and from cells exfoli- pressor genes, in a variety of common human cancers
ated from buccal mucous membranes (lane BC) and conjunctiva (lane (for an overview, see Herman et al. 1996). To date, no
CC) are heterozygous at intragenic loci. In the enucleated tumor (lane aberrant methylation has been identiﬁed in constitu-
RB), the paternal haplotype is lost. Since the mutation identiﬁed in
tional cells from patients with hypermethylation in tu-tumor sample M6306 creates a new NlaIII site in exon 11, PCR
mor cells. It has been shown that cis-acting elements areproducts from tumor DNA were digested almost to completion. The
101-bp and 112-bp fragments, which resulted from NlaIII digestion required to prevent de novo methylation at CpG islands
of mutant products, were not detectable in the diverse samples of of constitutively unmethylated genes (Brandeis et al.
constitutional DNA from the patient. The DNA size marker (‘‘M’’) 1994; Macleod et al. 1994). Thus, it is conceivable that
shows fragments of the lengths listed in ﬁgure 2.
structural alteration of these sequences can cause consti-
tutional hypermethylation of RB1 alleles if the alter-
ations occur prior to the generation of the normal meth-
In two tumors without LOH at Rbi2 and RB1.20, the ylation pattern during early embryonal development.
identical 6-kb EcoRV fragment downstream of exon 17 Most patients investigated in this study had single
was affected by a somatic deletion. This fragment is tumors that were too large to allow us to exclude unam-
located halfway between the intragenic loci RBi2 and biguously the presence of multifocal disease. However,
RB1.20, which are located in the 5 and the 3 third of two patients showed distinct multifocal tumors. In one
this gene, respectively. Hemizygous deletions involving of these patients, the larger of two tumors was sampled,
these regions are manifested as LOH, and, therefore, in for DNA analysis, at the time of enucleation. In this
sample (M3619), a splice mutation in intron 19 andtumors without LOH, a bias toward the detection of
Figure 5 Proportion of patients not yet operated on, plotted as a function of time, by application of the Kaplan-Meier method. A,
Comparison of results obtained from 53 patients with LOH and from 22 patients without LOH. The difference between the curves is not
signiﬁcant, when compared by use of the log-rank test (x2 õ .92; df Å 1). B, Comparison of results obtained from 9 patients with loss of the
paternal allele and from 14 patients with loss of the maternal allele, in the tumors (log-rank test: x2 õ .23; df Å 1). C, Comparison of results
obtained from 9 patients with a constitutional mutation and from 28 patients in which neither of the two mutations identiﬁed in the tumor
was detectable in peripheral blood DNA (log-rank test: x2 õ .5; df Å 1).
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LOH at intragenic and telomeric polymorphic loci, in- ing mutation (Cowell and Cragg 1996). Starting from
this prediction, Cowell and Cragg (1996) investigateddicative of mitotic recombination, were identiﬁed. How-
ever, peripheral blood DNA from this patient did not peripheral blood DNA of three patients with isolated
unilateral retinoblastoma whose tumors were treated be-show the splice mutation identiﬁed in the tumor. Despite
several attempts, PCR analysis of DNA extracted from fore the patients were 12 mo old, and they identiﬁed
constitutional RB1-gene mutations in two of them. Inmicrodissected archival tissue of the smaller-tumor focus
failed. In a recent study of the histopathology of retino- our series, three patients treated before the age of 12 mo
showed constitutional RB1-gene mutations, whereas, inblastoma, a meticulous examination of histological sec-
tions showed that most patients with isolated unilateral seven patients, neither of the two mutations identiﬁed
in the tumor was detected in peripheral blood. On thedisease have, in fact, multifocal tumors (Moll et al.
1996). The authors assumed that additional foci are due whole, there was no signiﬁcant difference in the age at
operation between patients with a constitutional muta-to paracrine growth stimulation by factors released from
the original tumor and concluded that multifocal tumors tion and those in whom neither of the two mutations
identiﬁed in the tumor was detected in peripheral bloodalso may occur in nonhereditary patients. However,
multifocal disease in patients without a mutation in pe- leukocytes.
All but one of the constitutional mutations were deter-ripheral blood DNA also may be caused by somatic
mosaicism. In one patient, who was enucleated at the mined to have occurred de novo, because the mutations
were not detected in peripheral blood DNA from theage of 2.3 mo, a new tumor focus was identiﬁed in the
other eye, at the age of 10 mo. To terminate tumor patients’ parents and siblings. A missense mutation, in
exon 4 of the RB1 gene (c411ArT; E137D), that wasgrowth, successive sessions of cryocoagulation were re-
quired. To our surprise, both mutations identiﬁed in the identiﬁed in both the tumor and the constitutional cells
of sample M2408 also was found in the patient’s motherenucleated tumor sample (M6306) were not detected in
the constitutional DNA of peripheral blood or in cells and sibling. Segregation analysis indicated that the mu-
tation is in phase with the grandpaternal haplotype.of cephalic origin. A similar patient with bilateral retino-
blastoma, whose ﬁbroblast DNA did not show the muta- Since the grandfather did not consent to DNA testing,
we cannot show whether this base substitution was in-tions identiﬁed in the tumor, also was reported by Shi-
mizu et al. (1994). When it is considered that only a few herited or whether it occurred de novo. An identical
mutation was reported previously in a patient with bilat-tumors have been investigated so far, it is intriguing to
ﬁnd such an unexpectedly high rate of cases that are eral retinoblastoma but was not identiﬁed in ú300 pa-
tients tested thus far (Blanquet et al. 1993, 1995; Loh-suggestive of somatic mosaicism. The screening of con-
stitutional DNA will fail to identify postzygotic muta- mann et al. 1996; this study). However, the putative
consequence of this mutation, a substitution of glutamictions, unless the analysis includes cells that are part of
the mutant clone. Therefore, mosaicism may contribute acid for aspartic acid, at position 137, is unusual in view
of the spectrum of missense mutations in the RB1 gene,to the lower rates of the detection of mutations in consti-
tutional DNA that are observed for patients with iso- because the substituted amino acids have very similar
properties. The sequence environment of this mutationlated retinoblastoma, as compared with the rates ob-
tained for familial cases (Blanquet et al. 1995). gives no clue as to whether splicing may be affected,
but mutations may have unexpected effects on splicingIn 6 (17%) of 36 patients, we identiﬁed one of the
mutations in the tumor and in constitutional DNA. In (Nakai and Sakamoto 1994). Thus, at present, we can-
not decide if this alteration is a predisposing mutationaddition, 3 (3.4%) of 89 patients showed constitutional
mutations that were ascertained by the genotyping of or a neutral variant.
Most mutations identiﬁed in patients with bilateralpolymorphic loci. None of these patients showed a new
tumor, in repeated follow-up investigations. However, retinoblastoma result in premature-termination codons
(Lohmann et al. 1996), and, on average, patients withone patient (sample M2205) died of metastatic disease
10 mo after the initial diagnosis of unilateral retinoblas- these mutations show more than three tumors per eye
(Munier et al. 1994; Lohmann et al. 1996). The actualtoma. In a recent retrospective survey of patients with
unilateral retinoblastoma, Abramson et al. (1994) ob- number of tumors developing in a patient depends on
the number of random second mutations that occur inserved new intraocular tumors in only 4 (1.2%) of 338
patients with isolated disease treated by enucleation, and predisposed cells. Given that the chance of a second
event follows a Poisson distribution (Knudson 1971)the last new tumor was identiﬁed before the patient
reached the age of 31 mo. Almost all of our patients and that a mean number of six tumors develops in the
eyes (Munier et al. 1994; Lohmann et al. 1996), unilat-were followed beyond this age, and, therefore, it is not
likely that any of them will develop a new tumor. eral disease is expected in õ10% of carriers of a null
allele. Distinct RB1-gene mutations, however, have beenIt has been inferred from Knudson’s (1971) two-hit
hypothesis that patients with an early presentation of identiﬁed in rare families with so-called low penetrance
and an unusually high proportion of unilateral diseaseunilateral tumors are likely to be carriers of a predispos-
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(Sakai et al. 1991a; Yandell et al. 1991; Onadim et al. clone also may be present in germinal tissue, the model
of mutational mosaicism can reconcile the apparently1992; Dryja et al. 1993; Lohmann et al. 1994a; Cowell
et al. 1996). One patient (sample G1142) in this study high rate of constitutional mutations identiﬁed in this
study with the signiﬁcantly lower rate of affected chil-carries a de novo missense mutation (R661W), which
was found to be associated with low penetrance in sev- dren observed among survivors of unilateral disease
(Draper et al. 1992).eral unrelated families (Yandell et al. 1991; Onadim et
al. 1992; Lohmann et al. 1994a). An increased propor- The signiﬁcance of mosaicism for genetic counseling
has been outlined previously (Carlson and Desnicktion of unilateral disease also has been noted in patients
with interstitial deletions involving 13q14 (Matsunaga 1979; Hall 1988). Possible mosaicism in some patients
also complicates molecular risk assessment for isolated1980). In view of these genotype-phenotype correla-
tions, unilateral presentation in one patient (sample retinoblastoma. As the presence of a mutant sector in
retinal tissue cannot be excluded, follow-up investiga-G1142) and in the two patients with cytogenetic dele-
tions identiﬁed here was to be expected. tions are required for all patients, regardless of their
constitutional genotypes. However, the identiﬁcation ofIn one patient (sample M2920), a mutation that re-
sults in the deletion of exon 13 is present in only some the two oncogenic mutations, in tumor samples, is a
prerequisite for the predictive testing of relatives. If theseperipheral blood leukocytes. Mutations resulting in the
identical in-frame deletion have been reported in previ- mutations are not detected in constitutional tissues, a
postzygotic origin has to be assumed, and, consequently,ous studies of patients with bilateral retinoblastoma
(Kato et al. 1994; Lohmann et al. 1996). Somatic mosa- siblings are not at risk. Nevertheless, a mutant clone
may be present in germinal tissues, and, therefore, theicism can be an important cause of phenotypic variation
in the expression of genetic traits (Hall 1988). Mosaic children of these patients have to be tested for the two
mutations. If a patient shows constitutional heterozy-deletions involving 13q14 have been observed in some
patients with retinoblastoma (Ribeiro et al. 1988), and gosity for an oncogenic mutation, siblings need to be
investigated, even if this mutation is not identiﬁed inthe results of a large study suggest that unilateral cases
are affected preferentially (Bunin et al. 1989). A milder either parent. Children of these patients are at a high
risk, although the segregation ratio may be skewed be-clinical presentation in patients with mosaic mutations
also has been reported in type 1 and in type 2 neuroﬁ- cause of germinal mosaicism. In conclusion, our results
emphasize that the manifestation and transmissibility ofbromatosis (Bourn et al. 1994; Colman et al. 1996).
Carlson and Desnick (1979) used mutational mosaicism retinoblastoma depend on the nature of the ﬁrst muta-
tion, its time in development, and the number and typesas a developmental model to analyze the origin, onset,
and transmissibility of retinoblastoma. They predicted of cells that are affected (Hall 1988).
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